ArticleBMC cancer2025
Peripheral circulating proteomic profiling reveals serum CD80 is positively correlated with the efficacy of neoadjuvant PD-1 blockade combined with chemotherapy for esophagus cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeoadjuvant immunotherapy combined with chemotherapy has achieved remarkable success in esophagus cancer. However, identifying the patients who may benefit from the neoadjuvant treatment remains a great challenge. The aim of this study was to investigate peripheral blood biomarkers and explore their underlying mechanism.
methodsBaseline blood samples were collected and analyzed from esophagus cancer patients (discovery cohort n = 46, validation cohort n = 28) treated with neoadjuvant PD-1 blockade combined with chemotherapy. To explore the underlying mechanism of the identified biomarker, pre- and post-treatment transcriptome sequencing and PD-L1 immunohistochemistry data were analyzed.
resultsA total of 55 features, including complete blood count and serum proteins were quantified from blood samples. In the discovery cohort, CD80-high patients were found to be associated with a higher response rate (AUC = 0.686). The predictive value of serum CD80 in evaluating treatment efficacy was further confirmed in the validation cohort (AUC = 0.778). Moreover, we found that patients with CD80-high were associated with higher CD8 T cells and lower neutrophils in the tumor microenvironment. During neoadjuvant treatment, iTreg infiltration and PD-L1 expression levels were significantly increased, while the MHC class I signature score was significantly decreased in patients with CD80-low.
conclusionsPeripheral blood circulating soluble CD80 protein may serve as a potential non-invasive biomarker to predict clinical benefit for esophagus cancer patients treated with neoadjuvant PD-1 blockade combined with chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.